Ulcerative colitis

被引:2008
作者
Ordas, Ingrid [1 ,3 ]
Eckmann, Lars [1 ]
Talamini, Mark [2 ]
Baumgart, Daniel C. [4 ]
Sandborn, William J. [1 ]
机构
[1] Univ Calif San Diego, Div Gastroenterol, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA
[3] Univ Barcelona, Div Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Ctr Invest Biomed Red Areatemat Enfermedades Hepa, Barcelona, Spain
[4] Humboldt Univ, Dept Med, Div Gastroenterol & Hepatol, Charite Med Ctr,Virchow Hosp,Sch Med, D-10099 Berlin, Germany
关键词
INFLAMMATORY-BOWEL-DISEASE; POUCH-ANAL ANASTOMOSIS; FACTOR-KAPPA-B; RANDOMIZED CONTROLLED-TRIAL; EVIDENCE-BASED CONSENSUS; NECROSIS-FACTOR-ALPHA; COLORECTAL-CANCER; CROHNS-DISEASE; RISK-FACTORS; DOUBLE-BLIND;
D O I
10.1016/S0140-6736(12)60150-0
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with proctitis or left-sided colitis might have a caecal patch of inflammation. Bloody diarrhoea is the characteristic symptom of the disease. The clinical course is unpredictable, marked by alternating periods of exacerbation and remission. In this Seminar we discuss the epidemiology, pathophysiology, diagnostic approach, natural history, medical and surgical management, and main disease-related complications of ulcerative colitis, and briefly outline novel treatment options. Enhanced understanding of how the interaction between environmental factors, genetics, and the immune system results in mucosal inflammation has increased knowledge of disease pathophysiology. We provide practical therapeutic algorithms that are easily applicable in daily clinical practice, emphasising present controversies in treatment management and novel therapies.
引用
收藏
页码:1606 / 1619
页数:14
相关论文
共 152 条
[41]
Disease Phenotype and Genotype Are Associated with Shifts in Intestinal-associated Microbiota in Inflammatory Bowel Diseases [J].
Frank, Daniel N. ;
Robertson, Charles E. ;
Hamm, Christina M. ;
Kpadeh, Zegbeh ;
Zhang, Tianyi ;
Chen, Hongyan ;
Zhu, Wei ;
Sartor, R. Balfour ;
Boedeker, Edgar C. ;
Harpaz, Noam ;
Pace, Norman R. ;
Li, Ellen .
INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) :179-184
[42]
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis [J].
Fuss, IJ ;
Heller, F ;
Boirivant, M ;
Leon, F ;
Yoshida, M ;
Fichtner-Feigl, S ;
Yang, ZQ ;
Exley, M ;
Kitani, A ;
Blumberg, RS ;
Mannon, P ;
Strober, W .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (10) :1490-1497
[43]
ILEAL POUCH ANAL ANASTOMOSIS - REOPERATION FOR POUCH-RELATED COMPLICATIONS [J].
GALANDIUK, S ;
SCOTT, NA ;
DOZOIS, RR ;
KELLY, KA ;
ILSTRUP, DM ;
BEART, RW ;
WOLFF, BG ;
PEMBERTON, JH ;
NIVATVONGS, S ;
DEVINE, RM .
ANNALS OF SURGERY, 1990, 212 (04) :446-454
[44]
Systematic review:: infliximab therapy in ulcerative colitis [J].
Gisbert, J. P. ;
Gonzalez-Lama, Y. ;
Mate, J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (01) :19-37
[45]
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis [J].
Gisbert, J. P. ;
Linares, P. M. ;
McNicholl, A. G. ;
Mate, J. ;
Gomollon, F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (02) :126-137
[46]
Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor [J].
Glocker, Erik-Oliver ;
Kotlarz, Daniel ;
Boztug, Kaan ;
Gertz, E. Michael ;
Schaeffer, Alejandro A. ;
Noyan, Fatih ;
Perro, Mario ;
Diestelhorst, Jana ;
Allroth, Anna ;
Murugan, Dhaarini ;
Haetscher, Nadine ;
Pfeifer, Dietmar ;
Sykora, Karl-Walter ;
Sauer, Martin ;
Kreipe, Hans ;
Lacher, Martin ;
Nustede, Rainer ;
Woellner, Cristina ;
Baumann, Ulrich ;
Salzer, Ulrich ;
Koletzko, Sibylle ;
Shah, Neil ;
Segal, Anthony W. ;
Sauerbrey, Axel ;
Buderus, Stephan ;
Snapper, Scott B. ;
Grimbacher, Bodo ;
Klein, Christoph .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21) :2033-2045
[47]
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial [J].
Hanauer, Stephen B. ;
Sandborn, William J. ;
Dallaire, Christian ;
Archambault, Andre ;
Yacyshyn, Bruce ;
Yeh, Chyon ;
Smith-Hall, Nancy .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 21 (12) :827-834
[48]
Characteristics of intestinal dendritic cells in inflammatory bowel diseases [J].
Hart, AL ;
Al-Hassi, HO ;
Rigby, RJ ;
Bell, SJ ;
Emmanuel, AV ;
Knight, SC ;
Kamm, MA ;
Stagg, AJ .
GASTROENTEROLOGY, 2005, 129 (01) :50-65
[49]
RANDOMIZED CONTROLLED TRIAL OF AZATHIOPRINE WITHDRAWAL IN ULCERATIVE-COLITIS [J].
HAWTHORNE, AB ;
LOGAN, RFA ;
HAWKEY, CJ ;
FOSTER, PN ;
AXON, ATR ;
SWARBRICK, ET ;
SCOTT, BB ;
LENNARDJONES, JE .
BRITISH MEDICAL JOURNAL, 1992, 305 (6844) :20-22
[50]
Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function [J].
Heller, F. ;
Fromm, A. ;
Gitter, A. H. ;
Mankertz, J. ;
Schulzke, J-D .
MUCOSAL IMMUNOLOGY, 2008, 1 :S58-S61